This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Malaria  • Drug Therapy, Other  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Malaria is one of the deadliest tropical diseases, causing more than 300 million infections yearly.¹ Successful clearance of the malarial parasites, Plasmodium species, from a patient’s body by antimalarial drugs is impeded by the emergence of drug-resistant strains. Drugs that effectively eliminate Plasmodium with short treatment duration reduce risk of treatment failure and emergence of drug-resistant strains.¹

Antimalarial drugs currently target single Plasmodium proteins. Effective therapeutic regimens require a combination of drugs that have different mechanisms of action during the same stage of the parasite’s life cycle.¹ However, malaria is a disease that occurs mostly in tropical and subtropical areas, where patients have limited access to drugs, and combination drug regimens may not succeed due to poor adherence.² Multitarget drugs are currently being used extensively to treat both infectious and inherited diseases.³ New antimalarial therapies that include multitarget drugs may have higher efficacy than single-target drugs and . . . [Full Text of this Article]

Methods

Ekachai Jenwitheesuk, DVM, PhD; Ram Samudrala, PhD
ram@compbio.washington.edu
Department of Microbiology
University of Washington School of Medicine
Seattle